

Bridgers SL, Ebersole JS: The clinical utility of ambulatory cassette EEG. *Neurology* 1985; 35:166-173

Guilleminault C, Connolly S, Winkle R, et al: Cyclical variation of the heart rate in sleep apnoea syndrome—Mechanisms and usefulness of 24 h electrocardiography as a screening technique. *Lancet* 1984; 1:126-131

Gyulay S, Gould D, Sawyer B, et al: Evaluation of a microprocessor-based portable home monitoring system to measure breathing during sleep. *Sleep* 1987; 10:130-142

Timms RM, Dawson A, Taft R, et al: Oxygen saturation by oxymetry: Analysis by microcomputer. *J Polysomnographic Technol* 1988, in press

Pulmonary Complications of the Acquired Immunodeficiency Syndrome

PULMONARY COMPLICATIONS are a major source of morbidity and mortality in patients with the acquired immunodeficiency syndrome (AIDS). Indeed, a sudden increase in the prevalence of *Pneumocystis carinii* pneumonia in otherwise healthy young homosexual men first alerted the medical community to this disease. The T-cell defect produced by the human immunodeficiency virus leaves these patients prey to numerous opportunistic pathogens and neoplasms that produce pulmonary disease.

Pneumocystis carinii is the major pulmonary pathogen occurring in 60% to 85% of patients with AIDS. The presenting symptoms include fever, cough, and dyspnea (85%), with chills (26%) and pleuritic chest pain (23%) occurring less frequently. A chest x-ray film is usually normal or shows diffuse interstitial infiltrates. Unilateral infiltrates and cavitary disease have been reported in patients with *P carinii* pneumonia. The alveolar-arterial oxygen difference is typically widened—> 15 torr, 92%—and portends a poor prognosis if greater than 25 torr. Although gallium lung scanning, the diffusing capacity for carbon monoxide, and exercise testing may be used for noninvasive assessments, a diagnosis rests on detecting organisms. Tests of induced sputum specimens may be positive 50% of the time, and transbronchial

lung biopsy combined with bronchoalveolar lavage has a 95% to 100% sensitivity. Pentamidine isethionate or trimethoprim-sulfamethoxazole, administered intravenously for two to three weeks, remains the mainstay of therapy. Prophylactic studies using nebulized pentamidine aerosol delivered into the bronchial tree are very encouraging. A 15% to 30% mortality is expected with each episode of *P carinii* pneumonia, however.

Other pulmonary infections associated with AIDS include *Cytomegalovirus* (15% to 34%), *Mycobacterium avium-intracellulare* (16% to 21%), *Mycobacterium tuberculosis* (4%), fungal infections (4%), and, most particularly, cryptococcal pneumonia, *Legionella pneumophila* (4%), and *Nocardia*. Because of a B-cell defect, AIDS patients also have a higher incidence of bacterial pneumonias (10%), chiefly caused by *Staphylococcus aureus*, primarily in association with pulmonary Kaposi's sarcoma.

There are also noninfectious causes of pulmonary infiltrates in this patient population. Kaposi's sarcoma is clinically and radiologically indistinguishable from *P carinii* pneumonia and accounts for about 10% of infiltrates. Pulmonary Kaposi's sarcoma is associated with a high mortality rate—88%. Nonspecific pneumonitis, on the other hand, generally carries a good prognosis and may be responsible for as high as 12% of the complications of AIDS.

JAMES TUCHSCHMIDT, MD
BISHER AKIL, MD
Los Angeles

REFERENCES

- Murray JF, Felton CP, Garay S, et al: Pulmonary complications of the acquired immunodeficiency syndrome—Report of a National Heart, Lung and Blood Institute workshop. *N Engl J Med* 1984; 310:1682-1688
- Polsky B, Gold JWM, Whimbey E, et al: Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104:38-41
- Solal-Celigny P, Couderc LJ, Herman D, et al: Lymphoid interstitial pneumonitis in acquired immunodeficiency syndrome-related complex. *Am Rev Respir Dis* 1985; 131:956-960

ADVISORY PANEL TO THE SECTION ON CHEST DISEASES

LOWELL E. RENZ, MD

Advisory Panel Chair

Section Editor

CMA Scientific Board Representative

GERALD L. MEYERS, MD
CMA Section Chair
Berkeley

EDWARD A. OPPENHEIMER, MD
CMA Section Secretary
Los Angeles

MITCHELL P. TARKOFF, MD
CMA Section Assistant Secretary
Oakland

PHILIP M. GOLD, MD
Loma Linda University

THOMAS A. RAFFIN, MD
Stanford University

GLEN LILLINGTON, MD
University of California, Davis

ARCHIE WILSON, MD
University of California, Irvine

DONALD TIERNEY, MD
University of California, Los Angeles

GENNARO M. TISI, MD*
University of California, San Diego

MICHAEL STULBARG, MD
University of California, San Francisco

OM P. SHARMA, MD
University of Southern California

IRA J. STRUMPF, MD
Woodland Hills

JOHN E. HODGKIN, MD
Deer Park

PHILIP HOPEWELL, MD
San Francisco

SPENCER K. KOERNER, MD
Los Angeles

*Deceased